IsoRay (ISR) delivered earnings and revenue surprises of -100% and 56.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced the successful completion of the merger with privately-held Viewpoint Molecular Targeting,...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Isoray, Inc (“the Company”) (NYSE: ISR)...
Profound Medical (PROF) delivered earnings and revenue surprises of 29.41% and 15.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, and Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Isoray, Inc. (NYSE: ISR) and Viewpoint Molecular Targeting, Inc. is fair to Isoray shareholders.
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 13.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Monday U.S. Economic Lookahead NAHB home builders' index (Sept.) Featured Earnings Autozone ...
Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -300% and 2.27%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?